Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
ROCKVILLE, MD, May 07, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at Deutsche Bank's 43rd Annual Health Care Conference in Boston on May 8, 2018 at 8:00 am (ET).
A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
